BC Week In Review | Apr 21, 2014
Company News

Adimmune, Valneva deal

Valneva granted vaccine manufacturer Adimmune rights to develop and commercialize Valneva's Japanese Encephalitis (JE) vaccine in Taiwan. Adimmune will be responsible for obtaining regulatory approval in the country and will market the vaccine under a...
BC Week In Review | Jul 29, 2013
Clinical News

Ixiaro regulatory update

The World Health Organization (WHO) awarded prequalification to Biological E's Japanese Encephalitis (JE) vaccine for worldwide use in adults. Biological E expects WHO to extend the prequalification to include pediatric use by year end. The...
BC Week In Review | Jul 15, 2013
Clinical News

Ixiaro regulatory update

Valneva said the U.S. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) expanded its recommendation for Ixiaro Japanese Encephalitis (JE) vaccine to include use in pediatric individuals ages >=2 months....
BioCentury | Jul 15, 2013
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) gained $1.91 (11%) to $19.40 Independence Day week after the European Commission approved Iclusig ponatinib to treat chronic myelogenous leukemia (CML) and Philadelphia-chromosome positive (Ph+) acute lymphoblastic leukemia (ALL)....
BC Extra | Jul 5, 2013
Financial News

Valneva raises EUR 40.2 million

Valneva SE (Euronext:VLA; VSE:VLA) raised EUR 40.2 million ($52.3 million) through the sale of 15.2 million shares at EUR 2.65 in a rights offering. Shareholders including Fonds Strategique d'Investissement and Groupe Grimaud were eligible to...
BC Week In Review | May 27, 2013
Clinical News

Ixiaro regulatory update

Intercell said FDA approved Ixiaro Japanese Encephalitis (JE) vaccine to include pediatric patients. The product is marketed for adults as Ixiaro in Canada, Europe, Hong Kong, Israel, Singapore and the U.S., where it has Orphan...
BC Week In Review | Feb 18, 2013
Clinical News

Ixiaro regulatory update

Intercell said the European Commission approved a regulatory application for Ixiaro Japanese Encephalitis (JE) vaccine to include pediatric patients. An application for the pediatric indication is under review in the U.S., where it has Orphan...
BC Week In Review | Jan 14, 2013
Company News

Inviragen, The Company for Vaccine and Biological Production No. 1 deal

VABIOTECH received exclusive rights to develop and commercialize in Vietnam, Cambodia and Myanmar a Japanese encephalitis (JE) vaccine based on Inviragen's cell-based JE production technology. Inviragen is eligible for milestones. VABIOTECH, which already markets a...
BC Week In Review | Dec 24, 2012
Company News

Intercell, Vivalis deal

Vivalis will merge with infectious disease company Intercell in a stock deal that values Intercell at about €132.5 million ($174.4 million). The combined company, which will be a public company named Valneva SE , will also...
BC Extra | Dec 18, 2012
Top Story

Vivalis to merge with Intercell

Vivalis S.A. (Euronext:VLS) will merge with infectious disease company Intercell AG (VSE:ICLL; OTCQX:INRLY) in a stock deal that values Intercell at about EUR 132.5 million ($174.4 million). The combined company, which will be a public...
Items per page:
1 - 10 of 55